Rafei-Shamsabadi D - Search Results

1

MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors.

Marschner D, Falk M, Javorniczky NR, Hanke-Müller K, Rawluk J, Schmitt-Graeff A, Simonetta F, Haring E, Dicks S, Ku M, Duquesne S, Aumann K, Rafei-Shamsabadi D, Meiss F, Marschner P, Boerries M, Negrin RS, Duyster J, Zeiser R, Köhler N. Marschner D, et al. JCI Insight. 2020 Mar 26;5(6):e132334. doi: 10.1172/jci.insight.132334. JCI Insight. 2020. PMID: 32125286 Free PMC article.

2

Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone.

Rafei-Shamsabadi D, Lehr S, von Bubnoff D, Meiss F. Rafei-Shamsabadi D, et al. Cancer Immunol Immunother. 2019 Sep;68(9):1417-1428. doi: 10.1007/s00262-019-02377-x. Epub 2019 Aug 17. Cancer Immunol Immunother. 2019. PMID: 31422446 Free PMC article.

3

Molecular characterization and natural history of linear porokeratosis: A case series.

Saleva-Stateva M, Hess M, Technau-Hafsi K, Weibel L, Badea MA, Boente MDC, Theiler M, Fiandrino MJ, Hoeger P, Zimmer A, Rafei-Shamsabadi D, Balabanova M, Fischer J, Boerries M, Has C. Saleva-Stateva M, et al. J Am Acad Dermatol. 2021 Dec;85(6):1603-1606. doi: 10.1016/j.jaad.2020.11.061. Epub 2020 Dec 3. J Am Acad Dermatol. 2021. PMID: 33279647 No abstract available.

4

Case Report: Blurred Vision and Eruptive Nevi - Bilateral Diffuse Uveal Melanocytic Proliferation With Mucocutaneous Involvement in a Lung Cancer Patient.

Rafei-Shamsabadi D, Schneider J, Trefzer L, Technau-Hafsi K, Meiss F, Ness T. Rafei-Shamsabadi D, et al. Front Oncol. 2021 Apr 13;11:658407. doi: 10.3389/fonc.2021.658407. eCollection 2021. Front Oncol. 2021. PMID: 33928039 Free PMC article.

5

Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.

Zaremba A, Philip M, Hassel JC, Glutsch V, Fiocco Z, Loquai C, Rafei-Shamsabadi D, Gutzmer R, Utikal J, Haferkamp S, Reinhardt L, Kähler KC, Weishaupt C, Moreira A, Thoms KM, Wilhelm T, Pföhler C, Roesch A, Ugurel S, Zimmer L, Stadtler N, Sucker A, Kiecker F, Heinzerling L, Meier F, Meiss F, Schlaak M, Schilling B, Horn S, Schadendorf D, Livingstone E. Zaremba A, et al. Eur J Cancer. 2021 Jul;152:139-154. doi: 10.1016/j.ejca.2021.04.032. Epub 2021 Jun 5. Eur J Cancer. 2021. PMID: 34102453

6

Esophageal carcinoma in severe recessive dystrophic epidermolysis bullosa-an underestimated complication?

Schwieger-Briel A, Trefzer L, Schumann H, Reimer-Taschenbrecker A, Rafei-Shamsabadi D, Meiss F, Has C. Schwieger-Briel A, et al. J Eur Acad Dermatol Venereol. 2022 Apr;36(4):e293-e295. doi: 10.1111/jdv.17826. Epub 2021 Dec 2. J Eur Acad Dermatol Venereol. 2022. PMID: 34807476 No abstract available.

7

Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma.

Braune J, Keller L, Schiller F, Graf E, Rafei-Shamsabadi D, Wehrle J, Follo M, Philipp U, Hussung S, Pfeifer D, Mix M, Duyster J, Fritsch R, von Bubnoff D, Meiss F, von Bubnoff N. Braune J, et al. JCO Precis Oncol. 2020 Nov;4:20-31. doi: 10.1200/PO.19.00174. JCO Precis Oncol. 2020. PMID: 35050727

8

Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy.

Rafei-Shamsabadi D, Lehr S, Behrens M, Meiss F. Rafei-Shamsabadi D, et al. Cancers (Basel). 2022 Jan 21;14(3):540. doi: 10.3390/cancers14030540. Cancers (Basel). 2022. PMID: 35158808 Free PMC article.

9

MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study.

Salzmann M, Pawlowski J, Loquai C, Rafei-Shamsabadi DA, Meiss F, Ugurel S, Schadendorf D, Meier F, Enk AH, Hassel JC. Salzmann M, et al. Eur J Cancer. 2022 May;166:24-32. doi: 10.1016/j.ejca.2022.02.008. Epub 2022 Mar 7. Eur J Cancer. 2022. PMID: 35272084

10

Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid-A Retrospective, Monocentric Study.

Schauer F, Rafei-Shamsabadi D, Mai S, Mai Y, Izumi K, Meiss F, Kiritsi D. Schauer F, et al. Among authors: rafei shamsabadi d. Front Immunol. 2022 Jul 22;13:953546. doi: 10.3389/fimmu.2022.953546. eCollection 2022. Front Immunol. 2022. PMID: 35936009 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters